candesartan cilexetil has been researched along with Proteinuria in 27 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 9.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis." | 9.10 | Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. ( Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002) |
| "Hypertension was well controlled by administration of candesartan cilexetil." | 7.72 | Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. ( Ishida, H; Omoto, K; Shimmura, H; Tanabe, K; Tokumoto, T; Toma, H, 2003) |
| "In this prospective, parallel, open study of 86 patients with CGN, we compared the effects on proteinuria and renal functions of 36 months with comparable blood pressure (BP) control achieved by candesartan cilexetil (candesartan, 4-12 mg/day) or benazepril hydrochrolide (benazepril, 2." | 5.13 | Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis. ( Fujiwara, H; Minatoguchi, S; Mori-Takeyama, U; Murata, I; Oda, H; Ohashi, H; Ohno, M; Ozaki, Y, 2008) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 5.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "The effect of the angiotensin II receptor blocker, candesartan cilexetil, on proteinuria was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 diabetes." | 5.11 | Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. ( Haneda, M; Kawamori, R; Kikkawa, R; Sakai, H, 2004) |
| "A prospective, randomised, double-blind, parallel-group, dose-response trial was conducted to investigate the antiproteinuric effect of candesartan cilexetil, the angiotensin II type 1 receptor blocker, in patients with chronic glomerulonephritis." | 5.10 | Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. ( Abe, K; Arakawa, M; Kikkawa, R; Kurokawa, K; Ogawa, N; Onoyama, K; Saruta, T; Tomita, K; Ueda, N, 2002) |
| "Hypertension was well controlled by administration of candesartan cilexetil." | 3.72 | Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. ( Ishida, H; Omoto, K; Shimmura, H; Tanabe, K; Tokumoto, T; Toma, H, 2003) |
| " Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo." | 3.71 | Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. ( Hayashi, M; Nakaya, H; Saruta, T; Sasamura, H, 2001) |
| "Candesartan cilexetil (1 mg/kg/day) and enalapril (10 mg/kg/day) were orally administered once a day for 4 weeks (the short-term experiment) or 16 weeks (the long-term experiment) to 5/6 nephrectomized rats beginning 15 weeks after the nephrectomy, that is, after they had already showed marked proteinuria." | 3.70 | Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Naka, T; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1999) |
| "To investigate the role of the renin-angiotensin system (RAS) on nephrosclerosis in salt-loaded, partially nephrectomized spontaneously hypertensive rats (SHR), we evaluated the effects of angiotensin II (ANGII) blockade on the progression of nephrosclerosis with an angiotensin type 1 receptor (AT1rec) antagonist [TCV-116 (TCV)] and an angiotensin-converting enzyme (ACE) inhibitor (enalapril) at the doses equivalent in reducing systemic blood pressure (BP)." | 3.69 | Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. ( Ikenaga, H; Kanno, Y; Okada, H; Saruta, T; Suzuki, H, 1995) |
| "Treatment with candesartan cilexetil lowered systemic blood pressure, normalized PGC at 10 weeks and greatly reduced proteinuria and allograft glomerulosclerosis at 24 weeks." | 3.69 | Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats. ( Azuma, H; Brenner, BM; Mackenzie, HS; Nagano, H; Rennke, HG; Tilney, NL; Troy, JL; Ziai, F, 1997) |
| "Hypertension is a risk factor for the two leading causes of death in renal transplant recipients: cardiovascular disease (CVD) and graft failure." | 2.75 | Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. ( Geiger, H; Heemann, U; Legendre, C; Lièvre, M; Martinez, F; Moulin, B; Mourad, G; Philipp, T; Schmieder, R, 2010) |
| " Candesartan was generally well tolerated; two patients withdrew for adverse events (fatigue and worsening glomerulopathy)." | 2.75 | Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. ( Bagdasorova, IV; Drozdz, D; Gimpel, C; Hainer, JW; Montini, G; Schaefer, F; Sorof, J; Sugg, J; Teng, R; van de Walle, J; van Hoeck, K; Zurowska, A, 2010) |
| "Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system." | 2.47 | Differential clinical profile of candesartan compared to other angiotensin receptor blockers. ( Cernes, R; Mashavi, M; Zimlichman, R, 2011) |
| "Perindopril was stopped after the 8-week administration of the two drugs." | 1.32 | [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis]. ( Amemiya, M; Ando, Y; Asano, Y; Honma, S; Iimura, O; Kusano, E; Muto, S; Tanba, K; Yanagiba, S, 2003) |
| "In vehicle-treated rats, proteinuria, glomerulosclerosis, interstitial mononuclear cell (MNC) infiltration and interstitial fibrosis developed." | 1.30 | Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. ( Fukuda, R; Imura, Y; Matsuo, T; Nagano, H; Nishikawa, K; Noda, M; Ohta, M; Shibouta, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (44.44) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Philipp, T | 1 |
| Martinez, F | 1 |
| Geiger, H | 1 |
| Moulin, B | 1 |
| Mourad, G | 1 |
| Schmieder, R | 1 |
| Lièvre, M | 1 |
| Heemann, U | 1 |
| Legendre, C | 1 |
| Schaefer, F | 1 |
| van de Walle, J | 1 |
| Zurowska, A | 1 |
| Gimpel, C | 1 |
| van Hoeck, K | 1 |
| Drozdz, D | 1 |
| Montini, G | 1 |
| Bagdasorova, IV | 1 |
| Sorof, J | 1 |
| Sugg, J | 1 |
| Teng, R | 1 |
| Hainer, JW | 1 |
| Azegami, T | 1 |
| Sasamura, H | 3 |
| Hayashi, K | 2 |
| Itoh, H | 2 |
| Cernes, R | 1 |
| Mashavi, M | 1 |
| Zimlichman, R | 1 |
| Kurokawa, K | 1 |
| Abe, K | 1 |
| Saruta, T | 6 |
| Arakawa, M | 1 |
| Kikkawa, R | 2 |
| Ueda, N | 1 |
| Onoyama, K | 1 |
| Tomita, K | 1 |
| Ogawa, N | 1 |
| Iimura, O | 1 |
| Kusano, E | 1 |
| Tanba, K | 1 |
| Yanagiba, S | 1 |
| Amemiya, M | 1 |
| Ando, Y | 1 |
| Honma, S | 1 |
| Muto, S | 1 |
| Asano, Y | 1 |
| Omoto, K | 1 |
| Tanabe, K | 1 |
| Tokumoto, T | 1 |
| Shimmura, H | 1 |
| Ishida, H | 1 |
| Toma, H | 1 |
| Homma, K | 1 |
| Kanda, T | 1 |
| Yoshioka, K | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Kumagai, H | 1 |
| Wakino, S | 1 |
| Haneda, M | 1 |
| Sakai, H | 1 |
| Kawamori, R | 1 |
| Simonetti, GD | 1 |
| von Vigier, RO | 1 |
| Konrad, M | 1 |
| Rizzi, M | 1 |
| Fossali, E | 1 |
| Bianchetti, MG | 1 |
| Ishiguro, K | 1 |
| Sakamaki, Y | 1 |
| Mori-Takeyama, U | 1 |
| Minatoguchi, S | 1 |
| Murata, I | 1 |
| Fujiwara, H | 1 |
| Ozaki, Y | 1 |
| Ohno, M | 1 |
| Oda, H | 1 |
| Ohashi, H | 1 |
| Yayama, K | 1 |
| Makino, J | 1 |
| Takano, M | 1 |
| Okamoto, H | 1 |
| Kanno, Y | 2 |
| Okada, H | 2 |
| Suzuki, H | 2 |
| Ikenaga, H | 2 |
| Kohara, K | 1 |
| Mikami, H | 1 |
| Okuda, N | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Shibouta, Y | 4 |
| Chatani, F | 1 |
| Ishimura, Y | 1 |
| Sanada, T | 1 |
| Ohta, M | 4 |
| Inada, Y | 1 |
| Nishikawa, K | 3 |
| Noda, M | 3 |
| Fukuda, R | 2 |
| Matsuo, T | 3 |
| Nagano, H | 3 |
| Imura, Y | 3 |
| Nakamura, T | 2 |
| Obata, J | 1 |
| Onizuka, M | 1 |
| Kimura, H | 1 |
| Ohno, S | 1 |
| Yoshida, Y | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Mackenzie, HS | 1 |
| Ziai, F | 1 |
| Azuma, H | 1 |
| Troy, JL | 1 |
| Rennke, HG | 1 |
| Tilney, NL | 1 |
| Brenner, BM | 1 |
| Suzuki, Y | 1 |
| Shirato, I | 1 |
| Okumura, K | 1 |
| Ravetch, JV | 1 |
| Takai, T | 1 |
| Tomino, Y | 1 |
| Ra, C | 1 |
| Otsuka, F | 1 |
| Yamauchi, T | 1 |
| Kataoka, H | 1 |
| Mimura, Y | 1 |
| Ogura, T | 1 |
| Makino, H | 1 |
| Sugimoto, K | 1 |
| Tsuruoka, S | 1 |
| Matsushita, K | 1 |
| Fujimura, A | 1 |
| Naka, T | 2 |
| Ushiyama, C | 1 |
| Shimada, N | 1 |
| Sekizuka, K | 1 |
| Ebihara, I | 1 |
| Koide, H | 1 |
| Nakaya, H | 1 |
| Hayashi, M | 1 |
| Nagano-Tsuge, H | 1 |
| Sekiguchi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period.[NCT00244621] | Phase 3 | 95 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria[NCT00280215] | Phase 3 | 0 participants (Actual) | Interventional | 2007-12-31 | Withdrawn (stopped due to Inadequate number of patients, lack of funding) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00244621)
Timeframe: From randomisation to day 28
| Intervention | Percent change (Median) |
|---|---|
| Atacand .05 mg | -11.1 |
| Atacand .20 mg | -40.6 |
| Atacand .40 mg | -50.0 |
(NCT00244621)
Timeframe: From randomisation to day 28
| Intervention | Percent change (Median) |
|---|---|
| Atacand .05 mg | 0.0 |
| Atacand .20 mg | -29.2 |
| Atacand .40 mg | 0.0 |
(NCT00244621)
Timeframe: From randomisation to end of double-blind treatment (4 weeks)
| Intervention | mm Hg (Mean) |
|---|---|
| Atacand .05 mg | -5.2 |
| Atacand .20 mg | -7.9 |
| Atacand .40 mg | -11.1 |
(NCT00244621)
Timeframe: From randomisation to end of double-blind treatment (4 weeks)
| Intervention | mm Hg (Mean) |
|---|---|
| Atacand .05 mg | -6.0 |
| Atacand .20 mg | -8.9 |
| Atacand .40 mg | -12.0 |
1 review available for candesartan cilexetil and Proteinuria
| Article | Year |
|---|---|
Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; | 2011 |
8 trials available for candesartan cilexetil and Proteinuria
| Article | Year |
|---|---|
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2010 |
Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2002 |
Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2004 |
Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Creatinine; Diabetes Mellitus, | 2004 |
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Chil | 2006 |
Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Benzimidazoles; Biphenyl Compounds; Bl | 2008 |
Effects of the angiotensin II receptor antagonist candesartan cilexetil on blood pressure and proteinuria in patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2000 |
18 other studies available for candesartan cilexetil and Proteinuria
| Article | Year |
|---|---|
Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Enzyme Inhibit | 2012 |
[Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2003 |
Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2003 |
Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
Topics: Aging; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles | 2007 |
Role of angiotensin II in the transforming growth factor-beta 1 expression of rat kidney in anti-glomerular basement membrane antiserum-induced glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Basement Membrane; Benzimidazoles; Biphen | 1995 |
Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Capto | 1994 |
Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzi | 1993 |
Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1995 |
TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 1996 |
Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1997 |
Candesartan prevents the progression of mesangioproliferative nephritis in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 1997 |
Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1997 |
Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis.
Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Basement Membrane; Benzimidazoles | 1998 |
Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in dahl salt-sensitive rats.
Topics: Acetylglucosaminidase; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; A | 1998 |
Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |
Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 1999 |
Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angioten | 2001 |
Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2001 |